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specific enzymes and proteins, including 5 ‑LO, 
5‑LO –activating protein (FLAP), LTC4 synthase, 
or LTA4 hydrolase.
3 The main products of the LT 
cascade are LTC4, LTD4, and LTE4 due to the pres‑
ence of cysteine, collectively named cysteinyl leu‑
kotrienes (CysLTs), whereas LTB4 is a potent che‑
moattractant of neutrophils. The final metabo‑
lite of CysLTs is LTE4, excreted in urine in an un‑
changed form or N ‑acetyl ‑LTE4.
1
The  measurement of the serum levels of 
CysLTs is not a reliable method of assessing their 
INTRODUCTION Leukotrienes (LTs) are potent 
lipid mediators, derived from the 5 ‑lipoxygenase 
(5 ‑LO) arachidonic acid pathway, originally known 
for their role in the pathophysiology of inflam‑
mation and asthma.1 The primary source of LTs 
are myeloid cells, but considerable amounts are 
produced in inflammatory tissues by endothe‑
lial cells and platelets by transcellular synthe‑
sis.1,2 LT biosynthesis is a complex process initi‑
ated at the nuclear envelope by arachidonic acid 
release from phospholipids; it requires a set of 
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ABSTRACT
INTRODUCTION Leukotrienes (LTs) may be involved in atherosclerosis and may contribute to cardiovas­
cular outcomes in CAD.
OBJECTIVES We aimed to compare the baseline LT production in patients with stable CAD (sCAD) and 
myocardial infarction (MI), and to assess whether an increased LT production is associated with major 
adverse cardiovascular events (MACEs) at 1 year after MI.
PATIENTS AND METHODS LTIMI (Leukotrienes and Thromboxane In Myocardial Infarction) was a single­
­center, prospective, observational study of patients with stable sCAD and MI. Urinary leukotriene E4 
(LTE4) levels were measured on admission, at 1 month, and at 1 year, using high ­performance liquid 
chromatography tandem mass spectrometry.
RESULTS Of the 404 patients screened, 289 were enrolled (110 with sCAD and 179 with MI; mean [SD] age, 
63.9 [10.9] years). Patients with MI had higher median (interquartile range [IQR]) levels of log ­transformed 
LTE4 (logLTE4) than those with sCAD (4.74 pg/mg creatinine [4–5.45] vs 4.51 pg/mg creatinine [3.99–4.86], 
respectively; P <0.001). Median (IQR) logLTE4 levels in patients with MI significantly decreased at 1 month 
to 4.37 pg/mg creatinine (3.81–4.95), and at 1 year to 4.16 pg/mg creatinine (3.55–4.85). The baseline 
urinary logLTE4 levels were similar in patients with MACEs and those without MACEs (median [IQR], 4.78 
pg/mg creatinine [4.01–5.56]) and 4.68 pg/mg creatinine [3.97–5.28], respectively; P >0.05). Multiple 
regression showed no relation between LTE4 levels and the incidence of MACEs.
CONCLUSIONS LT production assessed by urinary LTE4 excretion is higher in patients with MI than 
in those with sCAD; however, LTE4 levels at baseline do not differ between patients with and without 
MACEs at 1 year after MI.
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participate in the study. The study protocol com‑
plied with the Helsinki Declaration and was ap‑
proved by the Ethics Committee of Jagiellonian 
University (Kraków, Poland).
Study population The LTIMI study was conduct‑
ed between July 2011 and September 2014. Eligi‑
ble patients aged between 31 and 88 years were 
admitted either for scheduled coronary angiog‑
raphy (CA) because of sCAD or were diagnosed 
with MI (both ST ‑elevation MI [STEMI] and non –
ST ‑elevation MI [NSTEMI]) and transferred in 
a timely manner for revascularization. In the MI 
group, only patients with MI type I (atherothrom‑
botic, spontaneous) and symptoms lasting no 
longer than 24 hours were eligible for the study. 
The type of MI was evaluated based on the uni‑
versal definition of MI23,24 by 2 cardiologists that 
were not blinded to the clinical data of the pa‑
tients, including CA findings. 
The exclusion criteria for the MI group were: 
the lack of baseline LTE4 measurements, late 
presentation of MI (>24 hours from the first 
symptoms), MI other than type I, cardiogenic 
shock, history of coronary artery bypass graft‑
ing (CABG), severe valvular heart disease, symp‑
toms of acute infection, asthma, chronic ob‑
structive pulmonary disease exacerbation, use 
of anti leukotriene medications, severe chronic 
kidney disease (estimated glomerular filtration 
rate [eGFR] <30 ml/min/1.73 m2), liver cirrho‑
sis, malignancy, patient refusal to participate in 
the study, and noncompliance. Patients adminis‑
tered antiplatelet drugs other than acetylsalicylic 
acid and clopidogrel prior or after percutaneous 
coronary intervention (PCI) or those enrolled to 
any other interventional trial (being the most 
common exclusion criterion) were excluded from 
the study. In the sCAD group, an additional ex‑
clusion criterion was ad hoc PCI performed im‑
mediately after the diagnostic CA. The study flow 
chart is presented in FIGURE 1.
Study procedures Assessment at baseline Data 
on comorbidities, demographic characteris‑
tics, and history of presenting complaint were 
collected on admission in both groups of pa‑
tients—with sCAD and MI. On admission, stan‑
dard laboratory tests were performed including 
serial high ‑sensitivity troponin T measurements 
(hs ‑TnT) (Roche Diagnostics, Mannheim, Ger‑
many). Blood and urine samples were collected 
from each participant prior to the CA and stored 
immediately after centrifugation at –70°C for 
further analysis.
Leukotriene measurement CysLT levels were mea‑
sured in urine samples. In the sCAD group, the 
samples were collected in the morning before 
CA, whereas in the MI group—on admission (the 
mean [SD] time from symptoms to sample collec‑
tion was 9.21 [6.7] hours). Additionally, the sam‑
ples were collected at 1 ‑month and 1 ‑year follow‑
‑ups. Urinary LTE4 excretion was assessed with 
biosynthesis.4 However, the measurement of the 
urinary LTE4 concentration is a generally accept‑
ed method to estimate a systemic production of 
CysLTs, and hence to determine the activity of 
the 5 ‑LO pathway in vivo.5,6
As a class, LTs have recently been intensively 
studied for their role in atherosclerosis and in‑
flammation contributing to coronary artery dis‑
ease (CAD). With the recent advent of novel anti‑
‑inflammatory strategies added on to conven‑
tional prophylaxis reducing cardiovascular risk, 
the LT pathway has become the strategic aim of 
therapeutic investigations.7,8
The distinct role of LTs in human atheroscle‑
rosis is mostly attributed to their paracrine ac‑
tivities exerted through the receptors CysLTR1, 
CysLTR2, LTB4R1, and LTB4R2,9,10 which are ex‑
pressed in the walls of the aorta and coronary 
vessels. As a consequence, LTs are believed to 
promote vascular inflammation via increased 
leukocyte chemotaxis, enhance permeability and 
tissue and matrix degeneration, and contribute 
to the risk of plaque rupture with subsequent 
thrombosis.11,12
A series of preclinical studies provided some 
evidence that the 5 ‑LO pathway promotes the de‑
velopment, progression, and destabilization of 
atherosclerotic plaques, leading to abdominal 
aortic aneurysm formation,13 myocardial infarc‑
tion (MI),13-16 and stroke.17 Immunohistochemi‑
cal studies proved that in atherosclerotic vascu‑
lar lesions the key 5 ‑LO pathway enzymes and 
receptors were expressed and correlated with 
the severity of the lesions and plaque instability.18
The above findings have led to a hypothesis 
that LTs contribute to cardiovascular outcomes 
in CAD and MI.8 In a large population ‑based co‑
hort study, treatment with the LT receptor an‑
tagonist montelukast was associated with a low‑
er risk of recurrent stroke, but no further associ‑
ations with cardiovascular events were found.19 
Despite strong scientific rationale, only few stud‑
ies have addressed this issue in clinical trials at‑
tempting to modify the LT production by inhib‑
iting the 5 ‑LO pathway. Moreover, the results of 
these trials are conflicting.20,21
LTIMI (Leukotrienes and Thromboxane In 
Myocardial Infarction) was a prospective, obser‑
vational study that aimed to assess the associa‑
tion between arachidonic acid derivatives (LTs 
and thromboxane A2) and major adverse cardio‑
vascular events (MACEs) in patients with CAD. 
In a previous publication,22 we reported throm‑
boxane A2 as a predictor of cardiovascular out‑
comes in MI. In the current study, we aimed to 
compare the baseline production of LTs in stable 
CAD (sCAD) and MI and assess whether the high‑
er levels of LTs are associated with more frequent 
MACEs in a 1 ‑year follow ‑up after MI.
PATIENTS AND METHODS We conducted a single‑ 
‑ center, prospective, observational, pragmatic 
study in 2 parallel groups of patients with sCAD 
and MI. All patients gave informed consent to 
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the HPLC ‑MS/MS measurement.5 The results were 
expressed in picograms (pg) per mg urine creati‑
nine (pg/mg creatinine).
high ‑performance liquid chromatography tan‑
dem mass spectrometry (HPLC ‑MS/MS), validat‑
ed before in an asthmatic cohort.5 LTE4 levels were 
measured at the presence of an identical deuter‑
ated standard added to the urine sample before 
FIGURE 1 Study flow chart 
Abbreviations: CA, coronary angiography; CABG, coronary artery bypass grafting; CV, cardiovascular; LTE4, leukotriene E4; MACE, major adverse 
cardiovascular event; MI, myocardial infarction; NSTEMI, non–ST ­segment elevation myocardial infarction; PCI, percutaneous coronary intervention; 
sCAD, stable coronary artery disease; STEMI, ST ­segment elevation myocardial infarction
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MACE vs non–MACE, were tested with the t test, 
Mann–Whitney test, and Fisher exact test for cat‑
egorical variables. Correlations between variables 
were analyzed using the Pearson’s or Spearman’s 
rank correlation, as appropriate for the data dis‑
tribution. For the analysis of urinary LTE4 levels 
at subsequent time points, the 1 ‑way analysis of 
variance for repeated measures and the post hoc 
Tukey test were used. For the comparisons of 
LVEF with LTE4 levels, the Kruskal–Wallis test 
was used with the post hoc Mann–Whitney com‑
parison adjusted with Bonferroni correction.
The association between LTE4 levels and the in‑
cidence of the composite MACE was evaluated us‑
ing the multiple logistic regression model only in 
the MI group, because in the sCAD group there 
were only 4 MACEs. Explanatory variables were 
chosen in a stepwise approach on the basis of 
the Akaike Information Criterion. Regression 
modeling included prespecified baseline clinical 
and laboratory characteristics, namely, age, sex, 
body mass index, smoking history (pack ‑years), 
previous MI, diabetes mellitus, hypertension, 
multivessel disease, time from symptoms to PCI, 
LVEF during hospitalization, maximum hs ‑TnT 
level, high ‑sensitivity C ‑reactive protein (hs ‑CRP), 
eGFR, and logLTE4 concentrations. All tests were 
2 ‑tailed, with P values of less than 0.05 consid‑
ered significant.
All statistical analyses were performed using 
the R software, 3.1.2. version (R Development 
Core Team. [2009] R: A language and environ‑
ment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria) and 
STATISTICA 12 (StatSoft, Inc., Tulsa, Oklahoma, 
United States).
RESULTS Study population A total of 404 pa‑
tients were screened for the inclusion and exclu‑
sion criteria of the LTIMI study, and 289 patients 
were enrolled. The study flow chart is presented in 
FIGURE 1. In this group, 110 patients had sCAD and 
were admitted for diagnostic CA and the remain‑
ing 179 patients had MI type I and were referred 
for PCI (n = 162) or rescue CABG (n = 17). The sex 
distribution was similar in both groups; howev‑
er, patients with MI were older (mean [SD] age, 
66.26 [11.92] years vs 60.03 [7.7] years; P <0.001), 
more often had diabetes, symptoms of claudica‑
tion, and dyslipidemia (mean [SD] low ‑density 
lipoprotein cholesterol levels, 3.1 [1.14] mmol/l 
vs 2.7 [0.98] mmol/l; P = 0.001), and higher 
hs ‑CRP levels (mean [SD], 9.62 [23.1] mg/l vs 
3.43 [6.6] mg/l; P <0.001). The basic demograph‑
ic and clinical characteristics of the study groups 
are presented in TABLE 1.
Urinary leukotriene E4 excretion The median (IQR) 
LTE4 row data for sCAD and MI were as follows: 
91.14 (53.95–128.87) and 114.98 (55.3–232.42). 
All analyzes were performed on log ‑transformed 
data. The LTE4 excretion did not correlate with 
age, sex, or the laboratory parameters such as 
white blood cell count, hs ‑CRP, and hs ‑TnT. On 
Transthoracic echocardiography Standard trans‑
thoracic echocardiography (TTE) was performed 
on admission and at 1 year in all patients with 
sCAD and MI. Two experienced echocardiogra‑
phers–cardiologists, blinded to CysLT measure‑
ment results, assessed the images independently, 
according to current guidelines.25 Left ventricu‑
lar ejection fraction (LVEF) was calculated using 
the Simpson’s method.
Coronary angiography and percutaneous coronary 
intervention CA was performed in both study 
groups, using a standard technique, under local 
anesthesia by puncture of the femoral or radial ar‑
tery, with typical diagnostic catheters. The arterial 
access was selected at the discretion of the oper‑
ator. All patients were treated with primary PCI 
in the setting of STEMI, and immediate ad hoc 
PCI in the setting of high ‑risk NSTEMI. Most pa‑
tients underwent an immediate invasive strate‑
gy (0–2 hours) or early invasive strategy (within 
24 hours of diagnosis). No delayed invasive strat‑
egy (within 72 hours of diagnosis) was used in 
the setting of NSTEMI.
Follow -up Patients were followed for 1 year after 
enrollment to the study. All patients had 2 visits 
scheduled in an outpatient clinic: 1 month and 1 
year after hospitalization. At both follow ‑up vis‑
its, the research team collected data on the oc‑
currence of MACEs and verified the information 
based on hospital discharge notes and interviews 
with family members. Urine samples were collect‑
ed at both visits for LTE4 analyses.
Outcome measures There were 2 primary out‑
comes of the study: 1) to compare the LTE4 pro‑
duction between patients with sCAD and MI; 
and 2) to evaluate the impact of the urinary LTE4 
concentration on the occurrence of a composite 
MACE that occurred during 1 ‑year follow ‑up af‑
ter hospitalization for MI or sCAD. The composite 
MACE was defined as the occurrence of at least 1 
of 8 MACEs, prespecified before commencement 
of the study, namely, recurrent MI, stroke / tran‑
sient ischemic attack, cardiogenic shock, heart 
failure event, nonfatal cardiac arrest, need for 
rescue PCI or CABG, and cardiovascular death. If 
2 MACEs occurred in one patient (eg, recurrent 
MI and death), they were counted as one out‑
come. The exact definitions of MACEs are pro‑
vided in a previous LTIMI study publication re‑
porting thromboxane A2 biosynthesis in MI.
22
Statistical analysis Categorical variables were 
presented as counts (percentages), whereas con‑
tinuous variables were reported as mean (SD) or 
median with interquartile range (IQR), depend‑
ing on their distribution. Urinary LTE4 levels were 
log ‑transformed (natural logarithms; logLTE4) to 
approximate normal distribution for further anal‑
ysis. Assumption of normality was verified using 
the Kolmogorov–Smirnov test. The differenc‑
es between the following groups: MI and sCAD; 
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model. In the MI group, there were no differenc‑
es in the LTE4 production between patients with 
STEMI and those with NSTEMI.
Urinary leukotriene E4 excretion at 1 year Urinary 
LTE4 levels were additionally measured at 1 ‑month 
admission, patients with MI had higher levels of 
logLTE4 than patients with sCAD (4.74 pg/mg 
creatinine [IQR, 4–5.45] vs 4.51 pg/mg creati‑
nine [IQR, 3.99–4.86]; P <0.001; FIGURE 2). This dif‑
ference was irrespective of age, sex, or the effect 
of comorbidities in the multivariable regression 
TABLE 1 Demographic and clinical characteristics of the study groups
Parameter All patients 
(n = 289)
sCAD  
(n = 110)
MI  
(n = 179)
P valuea
Demographic characteristics
Age, y, mean (SD) 63.89 (10.9) 60.03 (7.7) 66.26 (11.92) <0.001
Female/male, n 94/195 40/70 54/125 0.49
Medical history
Diabetes mellitus, n (%) 83 (28.7) 24 (21.8) 59 (33) 0.045
PAD/claudication, n (%) 46 (15.9) 10 (9.1) 36 (20.1) 0.01
History of MI, n (%) 77 (26.6) 30 (27.2) 47 (26.2) 0.85
TIA/stroke, n (%) 18 (6.2) 4 (3.6) 14 (7.8) 0.15
Family history of CAD, n (%) 111 (38.4) 33 (30) 78 (43.6) 0.02
Dyslipidemia, n (%) 220 (76.1) 74 (67.2) 146 (81.6) 0.004
Current or previous smoking, n (%) 185 (64) 67 (60.9) 118 (65.9) 0.39
LVEF, mean (SD) 47.8 (14.2) 55.5 (12.6) 44.8 (13.7) <0.001
a Patients with sCAD versus patients with MI
Abbreviations: LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; sCAD, stable coronary artery 
disease; TIA, transient ischemic attack; others, see FIGURE 1
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FIGURE 2 Urinary 
log­transformed 
leukotriene E4 (logLTE4) 
excretion in patients 
with stable coronary 
artery disease (sCAD; 
n = 110) and myocardial 
infarction (MI; n = 179) 
at the entry to the study. 
Horizontal bar represents 
mean.
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did not correlate with LVEF either at the time of 
MI or at 1 year.
DISCUSSION In this study, we found that sys‑
temic CysLT production, measured by urinary 
LTE4 excretion, was increased during MI, as com‑
pared with patients with sCAD. Subsequently, af‑
ter an acute event, urinary LTE4 levels decreased 
during 1 month and progressively during 1 year, 
suggesting that LTs may be involved in the patho‑
physiology of MI. At the same time, we showed 
that CysLT levels at the index hospitalization for 
MI did not differ in patients who suffered MACEs 
during 1 ‑year follow ‑up, when compared with 
those without MACEs.
An increased LT production during acute MI 
has been reported in both experimental animal 
models and humans.2 The evidence for 5 ‑LO acti‑
vation was first shown by Carry et al14 in a group 
of 16 patients with MI treated with tissue plas‑
minogen activator and 14 patients with unstable 
angina.14 The LTE4 level decreased on the third 
day after the ischemic episode. A similar increase 
in the urinary LTE4 excretion was also evidenced 
by De Caterina et al,15 who measured LTE4 levels 
in small groups of 16 patients with NSTEMI, 6 
patients with STEMI, and 17 patients with sta‑
ble angina. They found that the mean values of 
urinary LTE4 levels are increased in patients in 
the setting of acute ischemia.15 Myocardial isch‑
emia induced by a positive exercise stress test 
was not accompanied by an increase in detectable 
levels of LTE4 in our study, while a significant in‑
crease was observed after PCI (n = 10), as com‑
pared with diagnostic CA (n = 9). This finding is 
consistent with a study by Rzeszutko et al,26 who 
and 1 ‑year follow ‑ups. In the MI group, the me‑
dian (IQR) logLTE4 level decreased from 4.74 pg/
mg creatinine (4–5.45) to 4.37 pg/mg creatinine 
(IQR, 3.81–4.95) at 1 month (P <0.05), and to 4.16 
pg/mg creatinine (3.55–4.85) at 1 year (P <0.05 
compared with the level at 1 month and P <0.0001 
compared with the baseline level). The LTE4 level 
at 1 month after MI was similar to the baseline 
LTE4 level in patients with sCAD (P = 0.051), and 
at 1 year, it was lower than the baseline level in pa‑
tients with sCAD (P = 0.02). In the sCAD group, 
the LTE4 level was stable during 1 ‑year follow ‑up 
(P >0.05). The changes in LTE4 levels in the sCAD 
and MI groups are shown in FIGURE 3.
Baseline urinary leukotriene E4 levels in patients with 
myocardial infarction with and without major adverse 
cardiovascular events during 1 -year follow -up In 
the sCAD group, there were only 4 MACEs dur‑
ing the 1 ‑year follow ‑up. Therefore, the analysis 
of MACEs was performed only in 179 patients 
with MI. In this group, there were 60 composite 
MACEs during the 1 ‑year follow ‑up, including 
10 cardiovascular deaths (FIGURE 1). The LTE4 pro‑
duction was similar between patients who expe‑
rienced MACEs (median [IQR], 4.78 pg/mg cre‑
atinine [4.01–5.56]) and those who did not (me‑
dian [IQR], 4.68 pg/mg creatinine [3.97–5.28]; 
P >0.05). In the multiple regression model, dia‑
betes mellitus, LVEF, and 3 ‑vessel disease were 
found to be associated with 1 ‑year MACEs, while 
the baseline LTE4 production in patients with MI 
was not. The results of the multivariable mod‑
el are shown in TABLE 2. The results of the regres‑
sion model did not change after adjustment for 
the diagnosis of STEMI vs NSTEMI. LTE4 levels 
FIGURE 3 Urinary 
log­transformed 
leukotriene E4 (logLTE4) 
during 1 ­year follow ­up 
in patients with stable 
coronary artery disease 
(sCAD; n = 102) and 
myocardial infarction 
(MI; n = 165). Data are 
presented as mean with 
SEM. 
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the fact that the CRP measurement has a limit‑
ed specificity for atherosclerosis ‑related inflam‑
mation, and its prognostic value for future car‑
diovascular events is particularly weak, especial‑
ly in patients who receive optimal medical pro‑
phylactic treatment including antiplatelet med‑
ications and statins as secondary prevention.28
CysLTs represent not only proinflammatory 
mediators, but also potent positive modulators 
of vascular permeability.29 The increased produc‑
tion of LTs during episodes of acute ischemia may 
not be related to the inflammatory destabilization 
of atheromatous plaque, but may result from in‑
travascular LT production by activated platelets 
and granulocytes. This transcellular mechanism 
of LT biosynthesis was proposed to be involved in 
ischemia/reperfusion injury, in which endotheli‑
al dysfunction was mediated by the CysLTR2 re‑
ceptor.30 Any direct vasoconstrictive effect of LTs 
has never been demonstrated in clinical trials on 
acute coronary syndromes, despite a casuistic de‑
scription of myocardial ischemia in a patient with 
extreme overproduction of LTs.31
Preclinical models of the LT pathway in myo‑
cardial ischemia–reperfusion injury are based pri‑
marily on genetically engineered mice. Despite 
experimental studies on multiple targets within 
the LT pathways, including 5 ‑LO, FLAP, LTC4 syn‑
thase, or CysLT1 and CysLT2 receptors, the im‑
pact of LTs on the pathogenesis of CAD and MI 
was not evidenced by unequivocal results.32 In 
particular, studies on CysLT receptors were het‑
erogeneous, thus raising doubts as to whether 
the 5 ‑LO pathway is involved in the pathogene‑
sis of CAD.30,33 The main concern about murine 
models of the LT pathway was the fast accelera‑
tion of atherosclerosis, which develops in mice 
within months, whereas in humans the disease 
progress takes decades. It was noted that the bio‑
synthesis of the 5 ‑LO pathway in murine athero‑
sclerosis may be restricted only to the early phase 
of the disease.32
Clinical genetic studies on genes determining 
the LT pathways also aroused some controversies. 
For example, certain variants of genes encoding 
FLAP and LTA4 hydrolase were associated with 
the risk of MI and stroke in European, Japanese, 
and African‑American populations, but they were 
not associated with MI and the risk of ischemic 
stroke in white North Americans.16,17,34,35 Two 
polymorphisms of the 5 ‑LO promoter were as‑
sociated with carotid intima–media thickness in 
the North American population, but were not as‑
sociated with an increased risk of MI in the Span‑
ish population.36,37 All these studies suggested 
a population ‑specific influence of polymorphisms 
in genes encoding the biosynthesis of the LT path‑
way, possibly explaining the lack of contribution 
of LTs to cardiovascular outcomes in MI.
Finally, the results of experimental studies in 
recent years raised legitimate hopes for the use 
of antileukotrienes, well known for their safe‑
ty of use in the treatment of asthma as an add‑
‑on therapy to the conventional cardiovascular 
observed the overproduction of urinary LTE4 dur‑
ing coronary interventions in patients with CAD. 
In acute coronary syndromes, including unstable 
angina, activation of the 5 ‑LO pathway extend‑
ed up to several months. A short ‑term activation 
of the 5 ‑LO pathway was reported after a coro‑
nary intervention in patients with sCAD, lasting 
a few hours after the procedure. These values re‑
turned to the baseline as early as 24 hours after 
the intervention.27 All the above reports corrobo‑
rate our findings and the hypothesis that LTs may 
participate in the pathomechanism of acute MI. 
However, further studies are needed to evaluate 
the potential causative role of LTs in the patho‑
genesis of MI.
The fact that baseline LTE4 levels are not elevat‑
ed in patients who after MI present with MACEs 
seems not to correlate with increased baseline 
LTE4 production. Several possibilities may account 
for this finding. This study provides clear evidence 
that LTE4 levels do not correlate with cardiovas‑
cular risk factors or specific cardiac biomarkers 
such as high ‑sensitivity troponins. There is also 
no correlation with systemic inflammatory mark‑
ers. In the current study, we determined the lev‑
els of hs ‑CRP, which is the most widely used in‑
flammatory marker in cardiovascular disease and 
the only reproducible indicator for which a stan‑
dardized assay has been developed. The inflam‑
matory profile of our study population was care‑
fully assessed and unified during recruitment by 
excluding patients with evidence of systemic in‑
flammation. Nevertheless, we should allow for 
TABLE 2 Multivariable logistic regression model for the prediction of major adverse 
cardiovascular events during 1 ­year follow ­up, including leukotriene E4
Parameter Adjusted 
OR
95% CI P value
Age, y 1.003 0.96–1.04 0.899
BMI, kg/m² 1.04 0.96–1.13 0.34
Smoking history, pack ­years 0.999 0.98–1.02 0.93
Time from symptoms to PCI, h 1.04 0.98–1.10 0.21
LVEF during hospitalization,% 0.96 0.93–0.99 0.01
Max hs ­TnT, μg/l 0.96 0.898–1.03 0.3
CRP, mg/l 0.99 0.98–1.01 0.97
EGFR, ml/min/1.73 m² 1.002 0.96–1.03 0.90
LogLTE4, pg/mg creatinine 1.23 0.89–1.699 0.21
Sex Male 1 Reference
Female 1.29 0.53–3.16 0.57
Diabetes No 1 Reference
Yes 2.78 1.2–6.45 0.02
Hypertension No 1 Reference
Yes 0.71 0.27–1.85 0.48
Multivessel disease 1­vessel 1 Reference
2 ­vessel 2.13 0.81–5.61 0.13
3 ­vessel 4.85 1.86–12.62 0.001
Abbreviations: BMI, body mass index; CI, confidence interval, CRP, C ­reactive protein; 
eGFR, estimated glomerular filtration rate, hs ­TnT, high ­sensitivity troponin T; 
others, see FIGURE 1 and TABLE 1 
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